舒心安神丸联合正念疗法治疗卒中后抑郁的临床研究

Clinical Study of Shuxin Anshen Pill Combined with Zhengnian Therapy in Treating Post-stroke Depression

目的:研究舒心安神丸联合正念疗法对卒中后抑郁(PSD)患者的临床疗效。方法:选取2021年5月—2023年2月于宁夏中医医院暨中医研究院脑病科住院及门诊PSD患者111例为研究对象,随机分为研究1组、研究2组及研究3组,各37例,无脱落病例。研究1组予以基础治疗,研究2组在研究1组基础上予以舒心安神丸治疗,研究3组在研究2组基础上予以正念疗法。比较三组神经功能、抑郁程度、中医证候评分、日常生活活动功能及安全性。结果:治疗2、4、8周后,三组美国国立卫生研究院卒中量表(NIHSS)及汉密尔顿抑郁量表(HAMD)评分均低于治疗前,差异有统计学意义(P<0.05);治疗2、4、8周后,研究3组NIHSS及HAMD评分低于研究1组、研究2组,差异有统计学意义(P<0.05)。治疗2、4、8周后,三组中医证候评分均低于治疗前,Barthel评分均高于治疗前,差异有统计学意义(P<0.05);治疗2、4、8周后,研究3组中医证候评分低于研究1组、研究2组,Barthel评分高于研究1组、研究2组,差异有统计学意义(P<0.05)。结论:舒心安神丸联合正念疗法能够有效改善PSD患者的临床症状,减轻神经功能损害程度,提高日常生活能力,疗效、安全性均较好。

Objective:To study the clinical efficacy of Shuxin Anshen pill combined with Zhengnian therapy in patients with poststroke depression(PSD).Methods:One hundred and eleven patients with PSD who were hospitalized and outpatients in the Department of Encephalopathy of Ningxia Hospital and Research Institute of Traditional Chinese Medicine from May 2021 to February 2023 were selected as the study subjects,and were randomly divided into study group 1,study group 2,and study group 3,with thirty-seven cases in each group,and there were no shedding cases.Study group 1 was treated with basic therapy,study group 2 was treated with Shuxin Anshen pill on the basis of study group 1,and study group 3 was treated with Zhengnian therapy on the basis of study group 2.The there groups were compared in terms of neurological function,depression level,traditional Chinese medicine symptom score,function of daily life activities and safety.Results:After 2,4 and 8 weeks of treatment,the National Institutes of Health Stroke Scale(NIHSS)and Hamilton Depression Scale(HAMD)scores of the three groups were lower than those before treatment,and the differences were statistically significant(P<0.05);after 2,4 and 8 weeks of treatment,the NIHSS and HAMD scores of study group 3 were lower than those of study group 1 and study group 2,and the difference was statistically significant(P<0.05).After 2,4 and 8 weeks of treatment,the traditional Chinese medicine syndrome scores of all three groups were lower than those before treatment,and the Barthel scores were higher than those before treatment,with statistically significant differences(P<0.05);after 2,4 and 8 weeks of treatment,the traditional Chinese medicine syndrome scores of study group 3 were lower than those of study group 1 and study group 2,and the Barthel score was higher than that of study group 1 and study group 2,with statistically significant differences(P<0.05).Conclusion:Shuxin Anshen pill combined with Zhengnian therapy can effectively improve the clinical symptoms of PSD patients,reduce the degree of neurological impairment,and improve the ability of daily life,with better efficacy and safety.